An Open-Label Study to Evaluate Retreatment With LIPO-202

An Open-Label Study to Evaluate Retreatment With LIPO-202

Evaluate the safety of three 8-week courses of treatment with LIPO-202 in non-obese patients who have central abdominal bulging. Efficacy measurements will also be collected.

Inclusion Criteria:

• Provided consent
• Healthy male or non-pregnant female subjects
• BMI < 30 kg/m2
• Stable diet and exercise routine
• Central abdominal bulging that is at least "Slight Bulge, Not Flat"

Exclusion Criteria:

• Have had any treatment of the fat around your abdomen, including surgical procedures (tummy tuck, liposuction), injections for fat loss or treatments with devices to reduce fat in your abdomen
• Plan on starting a weight loss or exercise program during the study.
• Be a woman who is pregnant, breast feeding, have had a baby within 6 months and/or not using appropriate birth control.
• Known hypersensitivity to study drugs
• Prior or current enrollment in any Neothetics (formerly Lithera) study involving LIPO-102 or LIPO-202